Complete revascularization is superior to culprit-lesion-only PCI in patients with both STEMI and multivessel disease, according to results from the COMPLETE trial, published Sept. 1 in the New England Journal of Medicine.

Research out of the Netherlands suggests current clinical guidelines might recommend overtreatment for women with heart failure, who see maximum benefit from HF drugs at half the dose of men.

Using donor hearts from patients who died of traumatic brain injury might be a more viable option for transplant candidates than previously thought, according to an analysis published in the Journal of the American Heart Association Aug. 30.

Biomedical tech company Biobeat has received 510K clearance for its noninvasive, cuffless BP-monitoring systems.

SGLT2 inhibitors—namely dapagliflozin—have been linked to a reduced risk of heart failure and death, as well as decreased odds of major adverse cardiovascular events.

Months after the latest losartan recall and more than a year after drug companies first started pulling bulk lots of angiotensin II receptor blockers (ARB) from pharmacy shelves, the FDA has issued a statement updating the American public on the scope of the situation.

Anxiety about rejection and abandonment in close relationships could be a risk factor for cardiovascular disease, a study out of Concordia University has found.

An editorial published in the latest issue of The Lancet suggests physicians might make quicker progress toward reducing global levels of uncontrolled hypertension if they reframe the condition as part of a patient’s whole health profile, rather than as an isolated disease.